JP2017513913A - 光学活性なｐｄｅ１０阻害剤 - Google Patents

光学活性なｐｄｅ１０阻害剤 Download PDF

Info

Publication number
JP2017513913A
JP2017513913A JP2016564604A JP2016564604A JP2017513913A JP 2017513913 A JP2017513913 A JP 2017513913A JP 2016564604 A JP2016564604 A JP 2016564604A JP 2016564604 A JP2016564604 A JP 2016564604A JP 2017513913 A JP2017513913 A JP 2017513913A
Authority
JP
Japan
Prior art keywords
compound
formula
disorder
converting
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016564604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513913A5 (enExample
Inventor
ニール エス． カッツホール，
ニール エス． カッツホール，
ケネス エム． ファーガソン，
ケネス エム． ファーガソン，
チャールズ プリンス ズタ，
チャールズ プリンス ズタ，
Original Assignee
オメロス コーポレーション
オメロス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オメロス コーポレーション, オメロス コーポレーション filed Critical オメロス コーポレーション
Publication of JP2017513913A publication Critical patent/JP2017513913A/ja
Publication of JP2017513913A5 publication Critical patent/JP2017513913A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016564604A 2014-04-28 2015-04-24 光学活性なｐｄｅ１０阻害剤 Pending JP2017513913A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461985381P 2014-04-28 2014-04-28
US61/985,381 2014-04-28
US201462047569P 2014-09-08 2014-09-08
US62/047,569 2014-09-08
PCT/US2015/027645 WO2015167968A1 (en) 2014-04-28 2015-04-24 Optically active pde10 inhibitor

Publications (2)

Publication Number Publication Date
JP2017513913A true JP2017513913A (ja) 2017-06-01
JP2017513913A5 JP2017513913A5 (enExample) 2018-05-31

Family

ID=54359189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564604A Pending JP2017513913A (ja) 2014-04-28 2015-04-24 光学活性なｐｄｅ１０阻害剤

Country Status (13)

Country Link
US (2) US9493447B2 (enExample)
EP (1) EP3137461B1 (enExample)
JP (1) JP2017513913A (enExample)
KR (1) KR102558505B1 (enExample)
CN (1) CN106255690B (enExample)
AU (1) AU2015253463B2 (enExample)
BR (1) BR112016024523B1 (enExample)
CA (1) CA2946754C (enExample)
ES (1) ES2895487T3 (enExample)
IL (1) IL248586B (enExample)
NZ (2) NZ716462A (enExample)
RU (1) RU2016146097A (enExample)
WO (1) WO2015167968A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513885A (ja) * 2014-04-28 2017-06-01 オメロス コーポレーション Ｐｄｅ１０阻害剤の調製のための方法および中間体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101713453B1 (ko) * 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
US20160284909A1 (en) * 2015-03-27 2016-09-29 Gabriel Harley Multi-diode solar cells
CA2980801A1 (en) * 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522228A (ja) * 2010-03-12 2013-06-13 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
JP6474430B2 (ja) * 2014-04-28 2019-02-27 オメロス コーポレーション Ｐｄｅ１０阻害剤の調製のための方法および中間体

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
EP0672031B1 (en) 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
DE4323192A1 (de) 1993-07-10 1995-01-12 Basf Ag Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen
DE4325846C1 (de) 1993-07-31 1995-01-19 Herberts Gmbh Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE4409501A1 (de) 1994-03-19 1995-09-21 Didier Werke Ag Verschleißfutter eines Schachtofens und Stein hierfür
CA2193725A1 (en) 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO1997027190A1 (en) 1996-01-22 1997-07-31 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
WO1998008830A1 (de) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
JPH1087543A (ja) 1996-09-17 1998-04-07 Chisso Corp アルコキシベンゼン誘導体、液晶組成物および液晶表示素子
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999045914A1 (en) 1998-03-13 1999-09-16 Maruho Kabushikikaisha Alkyl amine derivative and local anesthetic agent using the same
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
WO2000034251A1 (en) 1998-12-07 2000-06-15 Smithkline Beecham Corporation A method for quantitative determination of amino acids
IL144897A0 (en) 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
GEP20084399B (en) * 2001-05-22 2008-06-10 Pfizer Prod Inc Crystal forms of azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
EP1549600A1 (en) 2002-07-27 2005-07-06 AstraZeneca AB Ketones
US7662971B2 (en) 2002-10-08 2010-02-16 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
DE60324449D1 (de) 2002-10-30 2008-12-11 Via Pharmaceuticals Inc Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
WO2004052859A1 (ja) 2002-12-06 2004-06-24 Kowa Co., Ltd. エリスロポエチン産生促進剤
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
CN1809559B (zh) 2003-04-18 2010-06-02 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US7820704B2 (en) 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
BRPI0518508A2 (pt) 2005-01-07 2008-11-25 Pfizer Prod Inc compostos de quinolina heteroaromÁticos e seu uso como inibidores de pde10
MY158077A (en) 2005-02-04 2016-08-30 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions
US20060252807A1 (en) 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007027525A1 (en) * 2005-08-29 2007-03-08 Sanofi-Aventis U.S. Llc Novel crystalline form of a pyridazino [4 , 5-b] indole derivative
EP2107066A3 (en) * 2005-09-13 2009-10-21 Sicor, Inc. Processes for the synthesis of rocuronium bromide
TWI330639B (en) 2005-11-15 2010-09-21 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
US20080312305A1 (en) 2005-12-23 2008-12-18 Udo Bauer Imidazoles as Gaba- B Receptor Modulators
WO2007129183A2 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
DK2059234T3 (da) 2006-09-08 2011-11-28 Ore Pharmaceuticals Inc Fremgangsmåde til at lindre inflammation i fordøjelseskanalen
PL2076501T3 (pl) * 2006-09-25 2016-06-30 Ptc Therapeutics Inc Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US20090253918A1 (en) 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
ES2624791T3 (es) 2006-11-21 2017-07-17 Omeros Corporation Inhibidores de PDE10 y composiciones y métodos relacionados
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
EP2017264A1 (de) 2007-07-16 2009-01-21 Bayer Cropscience Ag Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2009049022A1 (en) 2007-10-10 2009-04-16 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
WO2010017236A1 (en) 2008-08-05 2010-02-11 Omeros Corporation Pde10 inhibitors and related compositions and methods
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522228A (ja) * 2010-03-12 2013-06-13 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
JP6474430B2 (ja) * 2014-04-28 2019-02-27 オメロス コーポレーション Ｐｄｅ１０阻害剤の調製のための方法および中間体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNARD HULIN ET AL: "Hypoglycemic Activity of a Series of α-Alkylthio and α-Alkoxy Carboxylic Acids Related to Ciglitaz", J. MED. CHEM., vol. 39, no. 20, JPN6019008030, 1996, pages 3897 - 3907, ISSN: 0003991651 *
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004178028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513885A (ja) * 2014-04-28 2017-06-01 オメロス コーポレーション Ｐｄｅ１０阻害剤の調製のための方法および中間体

Also Published As

Publication number Publication date
ES2895487T3 (es) 2022-02-21
CA2946754C (en) 2022-08-30
IL248586B (en) 2019-09-26
BR112016024523A2 (pt) 2017-08-15
US20170096420A1 (en) 2017-04-06
WO2015167968A1 (en) 2015-11-05
EP3137461A4 (en) 2017-09-13
AU2015253463A1 (en) 2016-11-03
US20160024070A1 (en) 2016-01-28
CN106255690B (zh) 2020-07-17
EP3137461A1 (en) 2017-03-08
CA2946754A1 (en) 2015-11-05
AU2015253463B2 (en) 2018-12-06
RU2016146097A (ru) 2018-05-30
EP3137461B1 (en) 2021-08-11
NZ630803A (en) 2016-03-31
IL248586A0 (en) 2016-12-29
KR102558505B1 (ko) 2023-07-21
RU2016146097A3 (enExample) 2018-11-15
CN106255690A (zh) 2016-12-21
US9493447B2 (en) 2016-11-15
KR20160141845A (ko) 2016-12-09
BR112016024523B1 (pt) 2022-10-11
NZ716462A (en) 2017-11-24
US9850238B2 (en) 2017-12-26

Similar Documents

Publication Publication Date Title
TW495498B (en) Amide derivative and a pharmaceutical composition containing the same as a Ca2+ release activated Ca2+ channel inhibitor
KR102558505B1 (ko) 광학 활성 pde10 저해제
Ohashi et al. Discovery of the investigational drug TAK-441, a pyrrolo [3, 2-c] pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility
AU2014249050B2 (en) Histone dementhylase inhibitors
CA2891976C (en) Imidazopyridine compounds
RU2545456C2 (ru) Pde10 ингибиторы и содержащие их композиции и способы
CA2802216C (en) Tetrahydrocarboline derivative and its use as an enpp2 inhibitor
JP2008526966A (ja) β−セクレターゼの阻害のためのアミノ−イミダゾロン
AU2011204370B2 (en) Hedgehog inhibitors
EP3590920A1 (en) 2-(substituted benzene matrix) aromatic formate fto inhibitor, preparation method therefor, and applications thereof
CN100482665C (zh) 吡唑并[1,5-a]嘧啶衍生物
WO2015189433A1 (en) Pyridazinones for the treatment of cancer
CN114685520B (zh) 三并环化合物及其药物组合物和应用
JP2018513153A (ja) Ｐｄｅ１０インヒビターならびに関連する組成物および方法
US9650368B2 (en) Processes and intermediates for the preparation of a PDE10 inhibitor
HK1235766B (en) Method of preparing an optically active pde10 inhibitor
HK1235766A1 (en) Method of preparing an optically active pde10 inhibitor
JPWO2019088057A1 (ja) アニリド誘導体及びその医薬用途
KR20230056618A (ko) Stat3 저해제로서 벤조싸이오펜-1,1-다이옥사이드 유도체 화합물 및 이의 용도
WO2023187471A1 (en) Heteroaryl derivative compounds, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191219